Prescient Therapeutics (ASX:PTX) is pleased to announce the appointment of Dr Rosalind Wilson as Chief Medical Officer. Read more 👉 https://t.co/IHJxIPvg5z
“I look forward to working with the team to advance these programs and unlock their full potential,” said Dr Wilson.
Prescient Therapeutics (ASX: PTX) recently held an insightful Investor Briefing with CEO, James McDonnell. James discussed why the FDA has fast tracked PTX-100, how our first-in-class technology could apply to 22% of all cancer cases, and more. Watch now: https://t.co/y36djk69z3
Prescient Therapeutics (ASX: PTX) is pleased to provide its Activities Report and Appendix 4C for the quarter ended 31 March 2026. CEO, James McDonnell will host an Investor Briefing on 5 May at 12pm (AEST). Register 🔗 https://t.co/PqtRNLkvxF
#Biotech#Health#CancerTreatment
Prescient Therapeutics (ASX: PTX) is pleased to release an update for the quarter ending 31 December 2025. James McDonnell will be hosting an Investor Briefing on 4th February at 11am (AEDT). Register 🔗 https://t.co/MUlxWDvD99
View announcement 🔗 https://t.co/xpf04mWryL
As we begin an exciting new year, Prescient Therapeutics (ASX: PTX) CEO, James McDonnell, caught up with @proactive_au to discuss what investors can expect in 2026. Watch now 👉 https://t.co/GuohqmkPur
🔗 Stay up-to-date on news: https://t.co/huln688Vhs
#Biotech
Special Report 📣 $PTX has raised $3m in a placement to sophisticated and professional investors following a $6.8m SPP for a total $9.8m to advance its pioneering cancer treatment therapy.
Read more 👉 https://t.co/OQbyX9hMSc
#Biotech#Health
Prescient Therapeutics $PTX is pleased to provide its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the June 2025 quarter.
View the announcement 👉 https://t.co/Eb0m0taVaw
#Biotech#Health#CancerTherapies#CancerTreatment
Special Report📣 $PTX has entered a critical stage where clinical data, regulatory support & commercial potential begin to converge in a defining moment for a biotech company aiming to bring a new therapy to market.
Read more @australian👉https://t.co/xX6boUZ0dN
#Health#Biotech
Gain insights on Prescient’s advanced cancer drug PTX-100, which is in its all-important Phase 2 clinical trials, & working to improve the lives of people suffering from cancers of unmet need👉 https://t.co/nFKZoQJHIs
🔗 Receive updates on $PTX: https://t.co/2DO7rEKwF0
#Biotech
It’s no secret that the rate of cancer both in Australia and overseas appears to be increasing - $PTX is working to improve the lives of people suffering from cancers of unmet need.
Learn more 👉 https://t.co/GymYG3YEx1
🔗 Stay up-to-date on PTX: https://t.co/7bcsqwApoE
#Health
Prescient Therapeutics $PTX CEO James McDonnell discusses the outstanding Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.
Watch now 👉 https://t.co/XmK3J8whNM
#CellTherapies#CancerTreatment#Biotech
Prescient Therapeutics $PTX has announced the completion of its first U.S. site visit for its Phase 2a trial of PTX-100 for patients with refractory or relapsed cutaneous T-cell lymphoma (r/r CTCL).
Learn more 👉 https://t.co/BAlKfDjuuq
#Biotech#Health#CancerTherapies
$PTX CEO James McDonnell chats with @StockheadAU Tylah Tully to discuss the company’s major milestone with the initiation of its first U.S. site for the Phase 2a trial of PTX-100.
Watch now 👉 https://t.co/bMVimyZ86G
#Health#Biotech#CancerTreatments
$PTX announces that the first U.S. Site Initiation Visit has been completed.
View 👉 https://t.co/0nmWyWaCEd
This marks a significant milestone in the progress of the Phase 2a trial for PTX-100 for patients suffering with refractory/relapsed Cutaneous T Cell Lymphoma.
#Biotech
🎧@SmallCapsASX Jess Fertig & $PTX CEO James McDonnell discuss the promising PTX-100 Phase 1b trial results & the designations received from the FDA which could allow Prescient to head toward a US$1.8bn market after Phase 2.
Listen now 👉 https://t.co/2xV0yRcF2f
#Biotech#Health
Special Report 📣 With a new leadership team and fast-track designation from the US Food and Drug Administration (FDA), clinical-stage oncology company $PTX is laser focused on development of lead compound PTX-100.
Read more👉 https://t.co/2Jg8x1pR0p
#Health#Biotech
Join Prescient Therapeutics (ASX: PTX) CEO James McDonnell at the Twilight Investor Briefing hosted by @MonsoonComms this Wednesday, 9th July in Melbourne CBD.
🔗 RSVP now: https://t.co/9CfiMKqJPz
#Biotech#Health
$PTX CEO James McDonnell chats with @StockheadAU’s Tylah Tully to discuss the promising PTX-100 Phase 1b trial results, and how the company is working to improve the lives of people suffering from cancers of unmet need. Watch now 👉 https://t.co/DiewDJJPuk
#Biotech#Health
One in five people will get cancer in their lifetime - Prescient Therapeutics $PTX is working to improve the lives of people suffering from cancers of unmet need. Read more 👉 https://t.co/ZUsnEE6eKh
🔗 Stay up-to-date on PTX: https://t.co/sLxqcVAkTb
#Health#CancerTreatments